Almotriptan (CAS: 155299-84-8) is a selective serotonin (5-HT_1B/1D) receptor agonist belonging to the triptan class of compounds. Its chemical formula is C₁₇H₂₅N₃O₂S, with a molecular weight of 335.47 g/mol. It appears as a white to off-white crystalline powder and is typically supplied at 95% purity or higher for pharmaceutical and research applications.

Almotriptan is primarily used in the acute treatment of migraine headaches with or without aura. It works by constricting dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides, thereby alleviating migraine-associated pain, nausea, vomiting, photophobia, and phonophobia. It is most effective when administered at the onset of symptoms, providing relief within 1-3 hours. Unlike some other triptans, almotriptan has a favorable pharmacokinetic profile with low inter-patient variability and minimal drug interactions.

As a specialty chemical and active pharmaceutical ingredient (API), almotriptan is utilized in drug development, clinical research, and formulation studies. It is available in tablet form for therapeutic use but also as a reference standard or intermediate in synthesis. Consult a healthcare provider for medical use; handle with care in laboratory settings following safety guidelines.